https://www.arabsciencepedia.org/w/index.php?action=history&feed=atom&title=%D8%A5%D9%8A%D8%AF%D9%88%D9%83%D8%B3%D9%8A%D8%AF%D9%8A%D9%86 2026-04-08T07:09:25Z تاريخ التعديل لهذه الصفحة في الويكي MediaWiki 1.43.6 https://www.arabsciencepedia.org/w/index.php?title=%D8%A5%D9%8A%D8%AF%D9%88%D9%83%D8%B3%D9%8A%D8%AF%D9%8A%D9%86&diff=37744&oldid=prev 2016-05-14T10:35:34Z

<p>أنشأ الصفحة ب&#039;{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443802525 | IUPAC_name = 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,...&#039;</p> <p><b>صفحة جديدة</b></p><div>{{Drugbox<br /> | Verifiedfields = changed<br /> | Watchedfields = changed<br /> | verifiedrevid = 443802525<br /> | IUPAC_name = 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione<br /> | image = Edoxudin.svg<br /> | alt =<br /> <br /> &lt;!--Clinical data--&gt;<br /> | tradename =<br /> | pregnancy_AU = &lt;!-- A / B1 / B2 / B3 / C / D / X --&gt;<br /> | pregnancy_US = &lt;!-- A / B / C / D / X --&gt;<br /> | pregnancy_category =<br /> | legal_AU = &lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&gt;<br /> | legal_CA = &lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&gt;<br /> | legal_UK = &lt;!-- GSL, P, POM, CD, or Class A, B, C --&gt;<br /> | legal_US = &lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&gt;<br /> | legal_status =<br /> | routes_of_administration =<br /> <br /> &lt;!--Pharmacokinetic data--&gt;<br /> | bioavailability =<br /> | protein_bound =<br /> | metabolism =<br /> | elimination_half-life =<br /> | excretion =<br /> <br /> &lt;!--Identifiers--&gt;<br /> | CAS_number_Ref = {{cascite|correct|??}}<br /> | CAS_number = 15176-29-1<br /> | ATCvet =<br /> | ATC_prefix = D06<br /> | ATC_suffix = BB09<br /> | DrugBank_Ref = {{drugbankcite|correct|drugbank}}<br /> | DrugBank =<br /> | UNII_Ref = {{fdacite|correct|FDA}}<br /> | UNII = 15ZQM81Y3R<br /> | PubChem = 66377<br /> | ChEMBL_Ref = {{ebicite|changed|EBI}}<br /> | ChEMBL = 318153<br /> | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}<br /> | ChemSpiderID = 59752<br /> | smiles = O=C/1NC(=O)N(\C=C\1CC)[C@@H]2O[C@@H]([C@@H](O)C2)CO<br /> | StdInChI_Ref = {{stdinchicite|changed|chemspider}}<br /> | StdInChI = 1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1<br /> | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}<br /> | StdInChIKey = XACKNLSZYYIACO-DJLDLDEBSA-N<br /> <br /> &lt;!--Chemical data--&gt;<br /> | C = 11 | H = 16 | N = 2 | O = 5<br /> | molecular_weight = 256.25514<br /> }}<br /> <br /> هو دواء مضاد للفيروسات. وهو مناظر لل[[ثيميدين]]، ال[[نوكليوزيد]]. وقد أظهر فعالية ضد فيروس الهربس البسيط.<br /> <br /> ==الاصطناع==<br /> <br /> [[File:Edoxudine synthesis.png|700px|center|thumb|Edoxudine synthesis:&lt;ref&gt;K. K. Gauri, GB 1170565; eidem, {{US patent|3553192}} (1968, 1971 both to Robugen).&lt;/ref&gt; Synthesis via organopalladium intermediates:&lt;ref&gt;{{Cite journal|doi=10.1021/ja00422a056|pmid=1249369|title=Synthesis of C-5 substituted pyrimidine nucleosides via organopalladium intermediates|year=1976|last1=Bergstrom|first1=Donald E.|last2=Ruth|first2=Jerry L.|journal=Journal of the American Chemical Society|volume=98|issue=6|pages=1587–9}}&lt;/ref&gt;&lt;ref name=&quot;BergstromOgawa1978&quot;&gt;{{cite journal|last1=Bergstrom|first1=Donald E.|last2=Ogawa|first2=Mark K.|title=C-5 substituted pyrimidine nucleosides. 2. Synthesis via olefin coupling to organopalladium intermediates derived from uridine and 2&#039;-deoxyuridine|journal=Journal of the American Chemical Society|volume=100|issue=26|year=1978|pages=8106–8112|issn=0002-7863|doi=10.1021/ja00494a014}}&lt;/ref&gt;]]<br /> <br /> <br /> {{Antibiotics and chemotherapeutics for dermatological use}}<br /> {{DNA antivirals}}<br /> <br /> [[Category:Pyrimidinediones]]<br /> <br /> <br /> {{antiinfective-drug-stub}}<br /> {{dermatologic-drug-stub}}</div>

سلام المجذوب